Telix Pharmaceuticals (ASX: TLX, NASDAQ: TLX) announced that the first patient has been dosed in the LUTEON Phase 3 clinical ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE